NEWS
Keep updated on EptivA Therapeutics activities.
EptivA Therapeutics Ltd. and Infopoly Ltd. today announce an expansion of their strategic alliance
OXFORD, 2nd December 2024 -
EptivA Therapeutics Ltd. and Infopoly Ltd. today announce an expansion of their strategic alliance, advancing technology to improve the translational development of new medicines for pain and beyond.
Following the successful development of Pain Cloud®, eptivA and digital technology expert Infopoly, announce an extension of their collaboration beyond pain into additional therapeutic areas such as neurology and oncology, with the goal of increasing the odds for new medicines.
ā
University of Surrey and EptivA Therapeutics announce partnership aimed at advancing the development of chronic pain medicines
OXFORD, 1st October 2024 — We are delighted to announce our new partnership with Dr Matt Parker and University of Surrey aimed at advancing the development of chronic pain medicines.
Dr Parker has recently been awarded a Short Industry Fellowship from the Royal Society to work with eptivA Therapeutics Ltd. researching a new personalised medication for those suffering from chronic pain.
ā
.jpg)
EptivA present PainCLOUD® at the International Association for the Study of Pain (IASP) World Congress 2024 Amsterdam
OXFORD, 9th August 2024 — It was a pleasure to attend International Association for the Study of Pain World Congress this week to present and discuss Pain Cloud® – our novel in-silico network biology methodology to develop personalized analgesics®.
ā
ā
Pain Cloud® Launch: A Collaboration between EptivA and Infopoly Ltd., creating an advanced solution to Pain Research.
OXFORD, 11th June 2024 — By partnering with the digital technology experts at Infopoly, Pain Cloud has been enhanced with a range of software tools to make its application as useful and effective as possible. Its network biology algorithm can be operated automatically, giving access to large data sets from high-quality molecular databases, providing unbiased analyses linking research targets to optimised disease phenotypes..
ā
EptivA Therapeutics Ltd. is pleased to announce that the new Pain Cloud® website is now live!
OXFORD, 1st June 2024 —
We have been working hard behind the scenes to create this new channel to give researchers access to our resources on Personalized Analgesics®.
Pain Cloud® is a novel digital solution, designed to increase the probability of success for analgesic clinical development, creating significant savings in project timelines and costs.
āā
EPTIVA THERAPEUTICS ANNOUNCES LICENSING AGREEMENT FOR EXCLUSIVE WORLDWIDE RIGHTS TO CLINICAL STAGE PERSONALIZED ANALGESICS® ASSET
OXFORD, 1st August 2022 — Eptiva Therapeutics Ltd., the first company to apply a precision medicine approach to developing new pain therapeutics, announces today that they have signed a licensing agreement with To Better Days Ltd. for worldwide exclusive rights to develop and commercialize their proprietary transdermal cholecalciferol patch in prescription indications.
ā
EptivA Therapeutics and Bayer enter into a contract research agreement
EptivA Therapeutics will utilize their proprietary Personalized Analgesics® research platform on Bayer’s research targets.
ā
EptivA Therapeutics will present at SMi's 22nd Pain Therapeutics Conference in London
EptivA Therapeutics CEO & Founder Mark Field will present at SMi's 22nd Pain Therapeutics Conference in London 4 - 5 May 2022 to discuss Personalized Analgesics® research and how it represents the first precision medicine approach to pain.
ā
02
Project Name
More news coming soon....
